Related Experiment Videos
Tailoring treatment for classical Kaposi's sarcoma: comprehensive clinical guidelines
B Brenner1, E Rakowsky, A Katz
1Institute of Oncology, Melanoma and Soft Tissue Tumor Board, Rabin Medical Center, Beilinson Campus, Petah Tiqva, Israel.
International Journal of Oncology
|May 26, 1999
Summary
Classical Kaposi's sarcoma (CKS) management guidelines are proposed. Observation may suffice for asymptomatic patients, while surgery, radiotherapy, or chemotherapy are options for advanced or symptomatic disease.
Area of Science:
- Oncology
- Dermatology
Background:
- Classical Kaposi's sarcoma (CKS) is a rare, slow-growing cancer.
- CKS disproportionately affects individuals of Ashkenazi and Mediterranean Jewish descent.
Purpose of the Study:
- To establish comprehensive management guidelines for Classical Kaposi's sarcoma.
- To analyze the effectiveness of various treatment modalities for CKS.
Main Methods:
- Retrospective analysis of 123 CKS patients.
- Focus on treatment modalities including observation, surgery, radiotherapy, and chemotherapy (vinblastine).
Main Results:
- CKS-related mortality was 4%.
- Observation: 38% progression-free; Surgery: 56% recurrence-free.
- Radiotherapy: 85% objective response; Chemotherapy (vinblastine): 73% objective response.
- Immunosuppression was the sole predictor of progression in observation-only patients.
Conclusions:
- Observation is suitable for immunocompetent, asymptomatic CKS patients.
- Surgery for symptomatic, resectable lesions.
- Radiotherapy for advanced or unresectable CKS.
- Chemotherapy for extensive disease or treatment failures.